AMMOM、CONAMEGER、FELAEN、FEMECOG、FEMECOT与ICAAFYD关于COVID-19应急期间骨质疏松患者管理的联合立场声明
该联合立场声明由墨西哥骨与矿物质代谢协会(AMMOM)、国家老年医学学院(CONAMEGER)、拉丁美洲内分泌学联合会(FELAEN)、墨西哥妇产科医学院联合会(FEMECOG)、墨西哥骨科与创伤学医学院联合会(FEMECOT)及瓜达拉哈拉大学体育活动与应用科学研究所(ICAAFYD)共同制定,针对COVID-19健康危机下骨质疏松患者的预防、诊断和治疗提供更新指导。工作组汇集骨专科多学科专家,快速汇总临床证据并生成证据报告,在发现证据缺口后形成专家共识意见,经4轮评审修改后批准初始指导声明(中高度共识),最终形成8个方面的指导声明。声明指出,鉴于现有证据水平低且文献快速演变,该指导作为「活文件」发布,预计未来更新。
要点
- 声明涵盖8个方面:骨折风险评估、风险优先级分层、骨密度扫描与实验室检查指征、药物治疗的启动与继续、治疗中断、新发骨折患者处理、物理治疗与跌倒预防、营养干预。
- 指导声明经4轮评审修改后获批,共识程度为中度至高度。
- 声明针对COVID-19应急期间骨质疏松患者的预防、诊断和治疗,而非普通时期常规管理。
- 因现有证据水平低且文献快速演变,该指导定位为「活文件」,预计未来更新。
研究设计与关键结果
- 制定机构:墨西哥骨与矿物质代谢协会(AMMOM)、国家老年医学学院(CONAMEGER)、拉丁美洲内分泌学联合会(FELAEN)、墨西哥妇产科医学院联合会(FEMECOG)、墨西哥骨科与创伤学医学院联合会(FEMECOT)、瓜达拉哈拉大学体育活动与应用科学研究所(ICAAFYD)。
- 方法:召集骨专科多学科工作组,快速汇总临床证据并生成证据报告;发现证据缺口后形成专家共识意见。
- 共识流程:初始指导声明经4轮评审修改后获批,共识程度为中度至高度。
- 最终指导声明涵盖:(1)骨折风险评估;(2)风险优先级分层;(3)骨密度扫描与实验室检查指征;(4)药物治疗的启动与继续;(5)治疗中断;(6)新发骨折患者处理;(7)物理治疗与跌倒预防;(8)营养干预。
证据类型、等级与局限
- 证据类型:多学会联合立场声明/专家共识。
- 证据水平:原文指出现有证据水平低。
- 共识程度:初始指导声明获中度至高度共识。
- 局限:原文指出现有证据水平低且文献快速演变,指导作为「活文件」发布,预计未来更新。
对床旁实践的改变
- 在COVID-19应急期间,骨质疏松管理应围绕骨折风险评估、风险优先级分层、骨密度扫描与实验室检查指征、药物治疗的启动与继续、治疗中断、新发骨折处理、物理治疗与跌倒预防及营养干预8个方面进行。
指南或共识出处
- Joint position statement on management of patient with osteoporosis during COVID-19 contingency from the AMMOM, CONAMEGER, FELAEN, FEMECOG, FEMECOT, and ICAAFYD(Arch Osteoporos)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. This joint position statement of Latin American Medical Societies provides an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis.
BACKGROUND: Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. Characterized by high contagiousness, significative morbidity, and mortality in a segment of those infected, it has overwhelmed health services and forced to redirect resources to the emergency while impacting the attention of acute non-COVID-19 and many chronic conditions.
OBJECTIVE: The objective of this study is to provide an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis.
METHODS: A task force, of bone specialists with a wide range of disciplines in the field of osteoporosis and fragility fracture, was convened with the representation of several professional associations, namely, the Mexican Association of Bone and Mineral Metabolism (AMMOM), the National College of Geriatric Medicine (CONAMEGER), the Latin American Federation of Endocrinology (FELAEN), the Mexican Federation of Colleges of Obstetrics and Gynecology (FEMECOG), the Mexican Federation of Colleges of Orthopedics and Traumatology (FEMECOT), and the Institute of Applied Sciences for Physical Activity and Sports of the University of Guadalajara (ICAAFYD). Clinical evidence was collated, and an evidence report was rapidly generated and disseminated. After finding the gaps in the available evidence, a consensus opinion of experts was made. The resulting draft was reviewed and modified accordingly, in 4 rounds, by the participants.
RESULTS: The task force approved the initial guidance statements, with moderate and high consensus. These were combined, resulting in the final guidance statements on the (1) evaluation of fracture risk; (2) stratification of risk priorities; (3) indications of bone density scans and lab tests; (4) initiation and continuation of pharmacologic therapy; (5) interruptions of therapy; (6) treatment of patients with incident fracture; (7) physical therapy and fall prevention; and (8) nutritional interventions.
CONCLUSION: These guidance statements are provided to promote optimal care to patients at risk for osteoporosis and fracture, during the current COVID-19 pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document" and future updates are anticipated.
参考来源
- Torres-Naranjo F, De la Peña-Rodríguez P, López-Cervantes RE, et al. Joint position statement on management of patient with osteoporosis during COVID-19 contingency from the AMMOM, CONAMEGER, FELAEN, FEMECOG, FEMECOT, and ICAAFYD. Arch Osteoporos. 2021. PMID: 33495916. doi:10.1007/s11657-020-00869-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。